An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

• Status: Completed
• Trial end date: 2014-04-01

Summary

Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the effect of impaired hepatic function on the PK of deferiprone and its 3-O-glucuronide metabolite following a single oral dose of 33mg/kg Ferriprox®.

• Phase: Phase 4

Details

• Lead Sponsor: ApoPharma
• Treatments: Deferiprone